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Abstract
Introduction: The C allele of the nonsynonymous Arg265His (rs3733591) variant of SLC2A9 confers risk for gout in
Han Chinese, Solomon Island and Japanese samples, with a stronger role in tophaceous gout. There is no evidence
for an association with gout in Caucasian populations. In the present study, we tested rs3733591 for association
with gout in New Zealand (NZ) Māori, Pacific Island and Caucasian samples.
Methods: Rs3733591 was genotyped across gout patients (n = 229, 232 and 327 NZ Māori, Pacific Island and
Caucasian samples, respectively) and non-gout controls (n = 343, 174 and 638 Māori, Pacific Island and Caucasian
samples, respectively). Further Caucasian sample sets consisting of 67 cases and 4,712 controls as well as 153 cases
and 6,969 controls were obtained from the Framingham Heart Study and the Atherosclerosis Risk in Communities
study, respectively. The Polynesian samples were analyzed according to Eastern and Western Polynesian ancestry.
Results: No evidence for risk conferred by the C allele of rs3733591 with gout was found in the sample sets of NZ
Māori (odd ratio (OR) = 0.98, P = 0.86), Eastern Polynesians (OR = 0.99, P = 0.92), Western Polynesians (OR = 1.16, P
= 0.36) or combined Caucasians (OR = 1.15, P = 0.13). The C allele was significantly overrepresented in Māori
tophaceous cases compared to cases without tophi (OR = 2.21, P = 0.008), but not in the other ancestral
groupings.
Conclusions: Noting that our study’s power was limited for detecting weak genetic effects, we were unable to
replicate associations of rs3733591 with gout in Eastern Polynesian, Western Polynesian and Caucasian samples.
However, consistent with a previous study of Han Chinese and Solomon Island populations, our data suggest that
rs3733591 could be a marker of severe gout in some populations. Our results also suggest that the effect of this
variant is population-specific, further confirming population heterogeneity regarding the association of SLC2A9 with
gout.
Introduction
Gout is a common form of inflammatory arthritis predo-
minantly affecting men, with hyperuricemia being an
essential predeterminant. As urate concentrations reach
saturation in the blood, monosodium urate (MSU) crys-
tals are deposited in the joints and tissues. An acute self-
limiting inflammatory reaction to these MSU crystals
leads to severe pain and debilitation (gout). Without
r e s o l u t i o n ,t h eM S Uc r y s t a l s and subsequent inflamma-
tion can lead to chronic tophaceous gout, bony erosions
and permanent disability. In New Zealand (NZ;
Aotearoa), gout is common in Māori and Pacific Island
men, with the prevalence estimated to range from 9.3%
to 13.9% and 14.9%, respectively [1,2]. Renal underexcre-
tion of uric acid has been determined to be an underlying
characteristic of gout and is more pronounced in people
of Māori and Pacific Island descent, and even more so in
patients with hyperuricemia and/or gout [3,4].
Genomewide association studies in Caucasian cohorts
have shown that intronic variants (rs7442295 and
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family 2, member 9/facilitated glucose transporter 9
(SLC2A9/GLUT9) gene are associated with high serum
urate concentrations and gout [5-10]. The intronic
SLC2A9 variant rs11942223 best explains the strong role
that SLC2A9 played in the development of gout in NZ
Māori, Pacific Island and Caucasian sample sets [11].
Interestingly, this variant is very rare in Chinese, Japa-
nese and Solomon Island people and does not play a
genetic role in the development of gout in these popula-
tions [12,13]. The intronic SLC2A9 variants have gen-
der-specific effects on serum urate, with the effect being
stronger in women [14].
SLC2A9 has been confirmed to be a renal urate trans-
porter [9,15,16]. It is a urate reuptake molecule that has
two isoforms, with the long-form being expressed on
the basal side and the short-form being expressed on
the apical side of the proximal renal tubule [17]. Mice
with overexpression of the long-form of SLC2A9 (also
k n o w na sh U R A T v 1 )o nt h eb a s o l a t e r a ls u r f a c eh a v ea
much greater reuptake of urate from the lumen into the
blood and reduced urinary urate excretion [15]. In con-
trast, overexpression of the URAT1 renal urate trans-
porter does not enhance urate reabsorption, indicating
that SLC2A9 is the rate-limiting step in urate reuptake
in mice [17].
An additional SLC2A9 variant, R265H (rs3733591),
contributes significantly to the development of elevated
urate concentrations and gout in Han Chinese, Solomon
Island and Japanese sample sets [12,13], but not in a
Caucasian sample set [8]. Han Chinese and Solomon
Island gout patients with the risk C allele had a higher
risk for tophi [12]. There are currently no data indicat-
ing how R265H may influence SLC2A9 function. Impor-
tantly, the effect of R265H in these populations is
independent of the previously gout-associated intronic
rs7442295/rs11942223 variants. The measure of linkage
disequilibrium, r
2, is < 0.05 between rs3733591 and
rs11942223 in HapMap Caucasian, Chinese and Japa-
nese samples. Given the existing evidence for population
heterogeneity in association of SLC2A9 variants (intro-
nic and R265H) with gout [8,11-13], we investigated a
possible role for R265H (rs3733591)i ng o u ti nN Z
Māori, Pacific Island and Caucasian case-control sample
sets in a study adequately powered to detect an effect
equivalent to that observed in other populations (odds
ratio (OR) > 1.4).
Material and methods
Study participants
Genotyping of NZ sample sets of Māori (229 cases and
343 controls), Pacific Island (232 cases and 174 controls)
and Caucasian (327 cases and 638 controls) was done
(Table 1). All cases were recruited from rheumatology
outpatient clinics, and their gout diagnoses were con-
firmed by a rheumatologist according to the American
College of Rheumatology preliminary diagnostic criteria
for acute gout [18]. The controls had no history of
arthritis and were recruited from the wider community.
Our recruitment of gout patients was approved by the
NZ Multi-region Ethics Committee (MREC 05/10/130),
and the recruitment of the controls was approved by the
Lower South and Multi-region Ethics Committees
(OTA/99/11/098 and MREC 05/10/130). All participants
provided written informed consent for the collection of
samples and subsequent analysis.
Given data from previous work investigating the
ABCG2 rs2231142 variant in the NZ sample sets [19],
along with knowledge of ancestral Polynesian and Māori
migration [20-22], the groups analyzed were Māori and
Eastern Polynesian (Māori and Cook Island), Western
Polynesian (Tonga, Samoa, Niue and Tokelau) and Cau-
casian. A total of 223 cases and 327 controls overlapped
between the Māori and Eastern Polynesian sample sets.
People of mixed Eastern and Western Polynesian ances-
try were excluded from the Eastern and Western Poly-
nesian sample sets.
Fifty-five gout cases were obtained from the Framing-
ham Heart Study (FHS) Offspring data set and com-
bined with 17 gout cases from the Generation 3 data.
Self-reported gout cases from the Offspring data set
were included if the participants reported having gout
on two or more survey occasions or reported having
gout on one survey occasion and were also taking antig-
out medication. Self-reported gout cases from the Gen-
eration 3 data set were included if the participants had
also answered “no” to taking medication for hyperten-
sion or high blood pressure. Control participants
included those who were Caucasian and were unrelated
to the gout patients. Genotypes were available for 67
gout cases and 4,712 control samples. One hundred
fifty-three self-reported Caucasian gout patients who
were not taking hypertensive medication were obtained
from the Atherosclerosis Risk in Communities (ARIC)
study and were compared to 6,969 unrelated controls.
Genotyping
The rs3733591 variant of SLC2A9 was genotyped across
the NZ Caucasian, Māori and Pacific Island sample sets
using the TaqMan Allelic Discrimination Assay Kit
(probe ID C__25803684_10; Applied Biosystems, Foster
City, CA, USA) and a LightCycler 480 Real-Time Poly-
merase Chain Reaction System (Roche, Indianapolis, IN,
USA).
Statistical analysis
A priori calculations were performed to test the power
of the NZ Polynesian sample sets to detect association
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[12,13]. Statistical power in the Māori, Eastern Polyne-
sian and Western Polynesian sample sets was 79%, 82%
and 58%, respectively (OR = 1.41, minor allele frequency
= 0.346).
Allelic and genotypic frequencies were compared
between case and control samples, and ORs and adher-
ence to the Hardy-Weinberg equilibrium were calcu-
lated using the SHEsis package [23]. The genotype
frequencies for rs3733591 were in Hardy-Weinberg
equilibrium (P > 0.01) for all case and control sample
sets.
Twenty-five biallelic markers were used as genomic
controls to account for differing levels of non-Māori
and non-Eastern Polynesian and non-Western Polyne-
sian ancestry between the case and control samples. The
stratification markers used were as follows: rs2075876
(AIRE), rs1816532 (ERBB4), rs13419122 (GFPT1),
rs12401573 (SEMA4A), rs6945435 (MGC87315),
rs743777 (IL2RB), rs10511216 (Intergenic), rs12745968
(FAM69A), rs1539438 (AP4B1), rs729749 (NCF4),
rs3738919 (ITGAV), rs1130214 (AKT1), rs755622 (MIF),
rs7901695 (TCF7L2), rs7578597 (THADA), rs2043211
(CARD8), rs10733113 (NLRP3), rs900865 (SOX6),
rs2059606 (PGDS), rs4129148 (PseudoY), rs831628
(CD59), rs7725 (GFPT), rs573816 (upstream of ALDOB),
rs1929480 (ALDOB) and rs12917707 (UMOD).T h e r e
was an average allele frequency difference of 0.22 (0.03
to 0.61) between a subset of 469 Māori cases and con-
trols and 505 Caucasian controls and a difference of
0.22 (allele frequency range 0.03 to 0.59) and 0.29 (0.04
to 0.67) between subsets of 417 Eastern Polynesian and
215 Western Polynesian cases and controls and 505
Caucasian controls, respectively. The genotype frequen-
cies for the stratification markers all exhibited Hardy-
Weinberg equilibrium P values > 0.003 for all case and
control sample sets. STRUCTURE [24] was used to
assign Māori, Eastern Polynesian and Western Polyne-
sian individuals into non-Caucasian populations (para-
meters: number of populations was assumed to be two,
Table 1 Demographic and clinical characteristics of gout cases and controls
a
Gout Controls
Characteristics Māori
b EP
b WP NZ
Caucasian
FHS ARIC Māori NZ EP NZ
WP
NZ
Caucasian
FHS ARIC
Number of cases/controls 229 261 187 327 67 153 343 348 142 638 47,12 6,969
Males, % 78 76 95 85 94 73 31 33 57 42 45 45
Mean ± 1 SD grandparents
of stated ancestry
2.87 ±
1.15
3.10 ±
1.07
3.72 ±
0.59
4.00 ±
0.00
- - 2.33 ±
1.20
2.46 ±
1.22
3.49 ±
0.86
4.00 ±
0.00
--
Mean serum urate at
recruitment, mmol/L (range)
0.45
(0.21 to
0.98)
0.47
(0.19 to
0.98)
0.49
(0.17 to
0.72)
0.41
(0.18 to
1.07)
0.42
(0.21 to
0.58)
0.42
(0.11-
0.70)
- - - - 0.29
(0.07 to
0.63)
0.34
(0.03 to
0.72)
Confirmed tophi, % 38 39 56 30 - - - - - - - -
Mean age at onset, years
(range)
39
(15 to
74)
39
(15 to
74)
34
(15 to
75)
47
(15 to 83)
----- - - -
Mean age at recruitment,
years (range)
--- - 3 8
(18 to
55)
54
(45-
65)
44
(17 to
80)
44
(17 to
85)
38
(17 to
86)
52
(17 to 95)
37
(5 to
72)
54
(44 to
66)
Mean gout attacks in past
year, n (range)
11
(0 to >
1/week)
11
(0 to >
1/week)
16
(0 to >
1/week)
7.5
(0 to > 1/
week)
----- - - -
First-degree relative with
gout, %
63 64 53 42 - - 30 31 23 14 - -
Allopurinol treatment, % 83 82 87 78 - - - - - - - -
Probenecid treatment, % 6 6 13 6 - - - - - - - -
Mean BMI (range) 35
(22 to
62)
35
(22 to
66)
38
(22 to
93)
30
(19 to 62)
29
(20 to
37)
28
(21-
41)
32
(20 to
77)
32
(20 to
77)
35
(21 to
63)
28 (19 to
56)
27
(15 to
61)
27
(15 to
56)
Type 2 DM, % 28 30 18 13 15 7 10 9 11 7 4 7
Hypertension, % 63 63 46 49 - - 16 16 17 14 - -
Dyslipidemia, % 51 52 53 48 - - 12 12 11 16 - -
Cardiovascular disease, % 40 38 20 37 - - 3 3 1 6 - -
Renal disease, % 30 30 22 22 21 - 2 2 1 2 6 -
aARIC = Atherosclerosis Risk in Communities study; BMI = body mass index; DM = diabetes mellitus; EP = Eastern Polynesian; FHS = Framingham Heart Study; NZ
= New Zealand; SD = standard deviation; WP = Western Polynesian.
bFull clinical data were available in 76% of Māori and 63% of EP gout cases (> 90% in other
sample sets).
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Monte Carlo replications after burn-in). The 505 Cauca-
sian control individuals were included in the STRUC-
TURE procedure to aid in population clustering as
being representative of the ancestral Caucasian popula-
tion. After running STRUCTURE on the Māori samples,
the proportions of samples in the inferred Caucasian
cluster were 0.95 for the 505 Caucasian controls and
0.06 for the total 572 Māori samples, 0.95 and 0.06 for
the 608 Eastern Polynesian samples and 0.98 and 0.05
for the 330 Western Polynesian samples. The STRUC-
TURE output was used to run STRAT [24] to test for
association (PSTRAT) of the variant with disease in the
presence of admixture. The phenotype of the 505 Cau-
casian individuals was set as unknown.
Gender and gender-genotype interaction analysis was
performed using Stata software (StataCorp, College Sta-
tion, TX, USA). Meta-analysis was performed to com-
bine data from independent data sets using rmeta
software (http://cran.r-project.org/web/packages/rmeta/
index.html) (within Stata) to calculate the combined
Mantel-Haenszel OR using a fixed effects model and the
Breslow-Day test for heterogeneity between studies.
Imputation of rs3733591 genotypes in the FHS and
ARIC samples was done with IMPUTE2 using HapMap3
CEU (NCBI Build 36, db126b) as reference data and a
quality threshold of 0.9.
Results
The demographic and clinical characteristics of study
participants are presented in Table 1 and genotype and
allele distributions of the rs3733591 variant are shown
i nT a b l e2 .T h e r ew a sn oe v i d e n c ef o ra na s s o c i a t i o n
of the risk C allele of rs3733591 with gout in any of
the Māori, Eastern Polynesian, Western Polynesian or
Caucasian analyses (OR = 0.98, PSTRAT =0 . 9 3 ;O R=
0.99, PSTRAT = 0.80; OR = 1.16, PSTRAT =0 . 6 5 ;a n d
OR = 1.15, PMeta =0 . 1 3 ,PBreslow-Day =0 . 8 4 ,r e s p e c -
tively). The r
2 values (measure of linkage disequili-
brium) between the previously associated SLC2A9
variant, rs11942223 [11], and the variant tested here,
rs3733591, were 0.04, 0.03, 0.04 and 0.05 for the
Māori, Eastern Polynesian, Western Polynesian and
Caucasian sample sets, respectively. Similarly, there
was no evidence for an association on the basis of
meta-analysis of the Easterna n dW e s t e r nP o l y n e s i a n
sample sets (OR = 1.05 (95% CI: 0.86 to 1.29); P =
0.62 and PBreslow-Day = 0.44, respectively). Meta-analysis
of data from Polynesian, Han Chinese, Solomon
Islands and Japanese sample sets (Table 2) [12,13]
indicated heterogeneity (PBreslow-Day = 0.05); however,
there was strong evidence for an association of
rs3733591 in these combined Asian-Pacific populations
(Figure 1) (OR = 1.29 (95% CI: 1.13 to 1.48, P =1 . 6×
10
-4). Addition of Caucasian data to the meta-analysis
weakened the overall effect; however, a strong associa-
tion was maintained (Figure 1) (OR = 1.24 (95% CI:
1.13 to 1.48); PBreslow-Day =0 . 1 3a n dP =1 . 1×1 0
-4).
A stronger effect of R265H with tophaceous gout has
been reported [12]; therefore, we tested whether the
effect of this variant is stronger in patients with tophi
than in patients without tophi. We found significant
overrepresentation of the C allele of rs3733591 in the
group with tophaceous gout in the Māori analysis (OR
=2 . 2 1 ,PSTRAT = 0.01), but not in the analyses of East-
ern Polynesian (OR = 1.53, PSTRAT =0 . 1 7 ) ,W e s t e r n
Table 2 Association analysis of rs3733591 with gout in NZ Māori, EP, WP and Caucasian sample sets and in the FHS
cohort
a
Case genotypes
b, n
(OR)
Control genotypes, n
(OR)
Sample
set
CC CT TT C-allele
frequency
CC CT TT C-allele
frequency
Genotypic
P
Allelic
P
PSTRAT Allelic OR, C allele
(95% CI)
Māori 101
(0.500)
83
(0.411)
18
(0.089)
0.705 164
(0.500)
138
(0.421)
26
(0.079)
0.710 0.92 0.86 0.93 0.98 (0.74 to 1.28)
EP 119
(0.513)
92
(0.397)
21
(0.091)
0.711 169
(0.506)
139
(0.416)
26
(0.078)
0.714 0.82 0.92 0.80 0.99 (0.76 to 1.28)
WP 39
(0.227)
88
(0.512)
45
(0.262)
0.483 33
(0.239)
57
(0.413)
48
(0.348)
0.446 0.17 0.36 0.65 1.16 (0.84 to 1.59)
NZ
Caucasian
217
(0.693)
87
(0.278)
9
(0.029)
0.832 417
(0.656)
196
(0.308)
23
(0.036)
0.810 0.49 0.23 - 1.17 (0.91 to 1.50)
FHS 44
(0.657)
21
(0.313)
2
(0.030)
0.813 3158
(0.670)
1,385
(0.294)
169
(0.036)
0.817 0.92 0.91 - 0.98 (0.63 to 1.51)
ARIC 117
(0.765)
30
(0.196)
6
(0.039)
0.863 4902
(0.704)
1,898
(0.272)
168
(0.024)
0.840 0.07 0.28 - 1.20 (0.86 to 1.67)
aARIC = Atherosclerosis Risk in Communities study; CI = confidence interval; FHS = Framingham Heart Study; OR = odds ratio; EP = Eastern Polynesian; NZ = New
Zealand; WP = Western Polynesian PSTRAT = STRAT test for association.
bThere was successful genotyping of 202 Māori cases (88%) and 328 Māori controls (96%),
232 EP cases (89%) and 334 EP controls (96%), 172 WP cases (92%) and 138 WP controls (97%) and 313 NZ Caucasian cases (96%) and 636 NZ Caucasian
controls (100%).
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(OR = 0.80, P = 0.33) population samples (Table 3).
Although the intronic SLC2A9 polymorphisms
(rs7442295/rs11942223) have shown gender-specific
effects on serum urate [14], there was no evidence for
rs3733591 exerting a gender influence in the gout sam-
ple sets comprising NZ Māori (C/C, C/T, T/T genotypes
in men and women were 78, 58 and 13 in men and 19,
Figure 1 Meta-analysis of association of rs3733591 with gout in Asian-Pacific ancestral groups without (top) and with (bottom) New
Zealand (NZ) Caucasians. ARIC = Atherosclerosis Risk in Communities study; CI = confidence interval; FHS = Framingham Heart Study.
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C/T, T/T genotypes were 91, 61 and 15 in men and 24,
23 and 4 in women; P = 0.55) or NZ Caucasians (C/C,
C/T, T/T genotypes in men and women were 187, 74
and 8 in men and 31, 13 and 1 in women; P =0 . 9 5 )
(Western Polynesian samples were not stratified accord-
ing to gender, as there were too few women (n =6 ) ) .
On the basis of logistic regression models, there was no
evidence of an interaction between rs3733591 genotype
and gender for the Māori, Eastern Polynesian or Cauca-
sian sample sets (P = 0.77, P =0 . 4 6a n dP =0 . 4 9 ,
respectively). There was also no evidence for an associa-
tion of rs3733591 with gout in the Māori, Eastern Poly-
nesian or Caucasian sample sets when only males were
analyzed (P = 0.59, P = 0.37 and P = 0.19, respectively).
Discussion
The R265H nonsynonymous SLC2A9 variant has pre-
viously been demonstrated to be associated with gout
and tophaceous gout in Han Chinese and Solomon
Islanders [12], and it is associated with the development
of gout in Japanese males [13]. We found no evidence
for an association of this variant with gout in Māori,
Eastern Polynesian, Western Polynesian or Caucasian
sample sets (Table 2). However, consistent with the data
from Han Chinese and Solomon Island sample sets [12],
we found that the C allele conferred an increased risk of
tophaceous gout in the Māori samples (OR = 2.21,
PSTRAT = 0.01), but not in the other sample sets (Table
3 ) .A tt h i ss t a g e ,t h es i m p l e s tc o n c l u s i o ni st h a tt h eC
allele of rs3733591 has a weaker effect on gout per se in
Caucasian and Polynesian populations than in the Asian
and Melanesian populations studied thus far. However,
it is very important to note that our sample sets had
insufficient power to detect an association at OR < 1.4,
although a priori power calculations indicated that they
were sufficiently powered to detect an effect of OR >
1.4, which is equivalent to the risk observed in the sam-
ple sets described by Tu et al.[ 1 2 ]a n dU r a n oet al.
[13]. Note that post priori power calculations for Eastern
and Western Polynesian sample sets using the actual
risk C-allele frequencies revealed similar power for OR
= 1.4 (78% and 57%, respectively).
Despite not finding any evidence for an association of
rs3733591 with gout in the Māori sample set (OR =
0.98), there was an effect conferred by the C allele when
the Māori cases were stratified for the presence or
absence of tophi (OR = 2.21). This supports the pre-
vious findings of Tu et al.[ 1 2 ] ,w h oc o n c l u d e dt h a t
rs3733591 might be a genetic checkpoint for tophaceous
gout. Whether this is true will require further study in
larger sample sets drawn from diverse ancestral groups.
In the Asia-Pacific region, an effect for rs3733591 in
tophaceous gout has been observed in the Han Chinese,
Solomon Island and Polynesian NZ Māori populations,
but not in Western Polynesian populations (Samoa,
Tonga, Niue). Why this is the case is unclear; however,
it is worth pointing out that unexpected heterogeneity
in genetic association with gout in the Asia-Pacific
region has also been documented at ABCG2 [19].
Furthermore, given that the C-allele frequency was simi-
lar between Māori and Caucasian sample sets (0.71 and
0.81, respectively, in controls), the disparate ORs for
tophaceous gout are notable (OR = 2.21 and OR = 0.88,
respectively, for tophaceous gout compared to nonto-
phaceous gout). The reason for this is unclear; it could
be a consequence of moderate sample size (power) or it
could reflect differences in disease pathogenesis between
the different population groups.
It is of interest that tophus formation is not consis-
tently present in all patients with long-standing hyperur-
icemia and gout, suggesting that additional factors may
regulate the development of these lesions. It is possible
that genetic variation in SLC2A9 is one of these factors.
SLC2A9 is expressed in the chondrocytes of human
articular cartilage [25]. The minor allele of R265H
(rs3733591, or one in linkage disequilibrium) may influ-
ence the activity of SLC2A9 in articular chondrocytes
and increase the risk for deposition of MSU crystals and
formation of tophi in joint structures. A further issue is
Table 3 Rs3733591 and tophaceous gout in the Māori, EP, WP and NZ Caucasian cases
a
Tophaceous cases, n (OR) Nontophaceous cases, n (OR)
Sample
set
CC CT TT C-allele
frequency
CC CT TT C-allele
frequency
Genotypic
P
Allelic
P
PSTRAT Allelic OR, C allele
(95% CI)
Māori 36
(0.692)
13
(0.250)
3
(0.058)
0.817 37
(0.446)
37
(0.446)
9
(0.108)
0.669 0.02 0.008 0.01 2.21 (1.22 to 4.01)
EP 43
(0.652)
17
(0.258)
6
(0.091)
0.780 48
(0.490)
41
(0.418)
9
(0.092)
0.699 0.09 0.10 0.17 1.53 (0.92 to 2.55)
WP 22
(0.234)
46
(0.489)
26
(0.277)
0.479 16
(0.213)
41
(0.547)
18
(0.240)
0.487 0.76 0.88 0.54 0.97 (0.63 to 1.48)
NZ
Caucasian
63
(0.656)
30
(0.313)
3
(0.031)
0.812 158
(0.715)
57
(0.258)
6
(0.027)
0.844 0.58 0.33 - 0.88 (0.51 to 1.24)
aCI, confidence interval; OR, odds ratio; CI, confidence interval; EP, Eastern Polynesian; NZ, New Zealand; WP, Western Polynesian; PSTRAT = STRAT test for
association.
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bute to the development of tophi; quantitative analysis
of tophus histology indicates that, in contrast to the
innate immune responses that are activated in acute
gout, both innate and adaptive immunity are implicated
in the development of the tophus [26]. Thus different
immune responses to MSU crystals may lead to different
manifestations of disease.
Interestingly, the C-allele risk variant of rs3733591 is
the minor allele in control sample sets of Han Chinese
(controls = 0.32) [12] Solomon Islanders (controls =
0.40) [12], Japanese (controls = 0.32) [13] and Western
Polynesians (controls = 0.43), yet it is the major allele in
sample sets taken from the FHS (controls = 0.82), NZ
Caucasians (controls = 0.81) and Eastern Polynesians
(controls = 0.71) (Table 2). There is a large shift in the
minor allele frequency between Eastern and Western
Polynesian sample sets, and such a change in allele fre-
quency is consistent with that seen at another gout
locus, ABCG2 (rs2231142) (the risk allele frequency is
0.29 in Western Polynesians, 0.13 in Caucasians and
0.10 in Eastern Polynesians) [19]. It can be observed
that, as the frequency of the rs3733591 Ca l l e l e
increases, the risk conferred by rs3733591 for gout
decreases, suggesting that population allele frequency is
important at R265H to detect an effect on the risk of
gout. It is also notable that the situation is reversed for
the SLC2A9 intronic variants (rs11942223 and surro-
gates), with a strong association in Caucasian [5-7,9,10]
and Polynesian populations (driven by protective haplo-
t y p e s )[ 1 1 ] ,b u tn o ti nM e l a n e s i a na n dA s i a np o p u l a -
tions, studied thus far [12,13].
In Caucasians, in addition to R265H, there are other
nonsynonymous genetic variants within SLC2A9, includ-
ing A17T (rs6820230), G25R (rs2276961), V253I
(rs16890979)a n dP 3 2 1 L( rs2280205)[ 7 ] .O n l y
rs16890979 is associated with gout in Caucasians [7,11],
possibly because of linkage disequilibrium with the
more strongly associated intronic variants that include
rs6855911 and rs11942223 [7,11]. Rs16890979 is also
associated with gout in Polynesians; however, this is also
likely to be secondary to an association with the intronic
variants [11]. The minor allele of rs16890979 is rare in
Han Chinese and Japanese [12,13]. Of the other variants,
only P321L has been tested for association with gout in
an Asia-Pacific region population (Japanese), in whom
there was no evidence for association [13]. The impact
of these nonsynonymous variants on the function of
SLC2A9 has not been reported to date.
Given the heterogeneity evident in risk conferred for
gout at SLC2A9 and ABCG2 in the Asian and Austrone-
sian populations studied so far, further investigation of
these genes in samples derived from Asian and Austro-
nesian people is warranted. These populations have
shared geographical history, although it is increasingly
evident that considerable genetic heterogeneity exists
w i t h i nA s i a n sa n dA u s t r o n e s i a n s ,a tl e a s ti ng o u ta n d
possibly in other complex diseases.
Conclusions
We were unable to replicate association of the
rs3733591 variant with gout in NZ Eastern Polynesian,
Western Polynesian or Caucasian sample sets. It is pos-
sible that rs3733591 has a weak effect in these popula-
tions; however, our study’sp o w e rw a sl i m i t e dt o
detecting an effect less than that previously reported
(OR = 1.4). However, consistent with a previous study
in Han Chinese and Solomon Islanders, our data suggest
that rs3733591 could be a marker of severe gout in
some populations.
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